Also, while PI3K inhibitors such as wortmannin are potential anti-cancer agents on their own [54], a more nearly complete inhibition of mTORC1 may be achieved when inhibitors of the PI3K/AKT pathway are administered in conjunction with rapamycin (Fig. 1). These results suggest a potentially important role of PRAS40 in the translational control of tumor progression. Here, AKT1 is linked to cancer.